VaxcytePCVX
PCVX
About: Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
Employees: 414
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
87% more call options, than puts
Call options by funds: $48.1M | Put options by funds: $25.7M
62% more repeat investments, than reductions
Existing positions increased: 139 | Existing positions reduced: 86
1.79% more ownership
Funds ownership: 111.15% [Q3] → 112.94% (+1.79%) [Q4]
0% more first-time investments, than exits
New positions opened: 61 | Existing positions closed: 61
2% less funds holding
Funds holding: 324 [Q3] → 318 (-6) [Q4]
25% less capital invested
Capital invested by funds: $15.5B [Q3] → $11.5B (-$3.94B) [Q4]
48% less funds holding in top 10
Funds holding in top 10: 23 [Q3] → 12 (-11) [Q4]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$90
206%
upside
Avg. target
$129
340%
upside
High target
$160
444%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
Needham Joseph Stringer 29% 1-year accuracy 30 / 103 met price target | 206%upside $90 | Buy Reiterated | 8 Apr 2025 |
Goldman Sachs Chris Shibutani 25% 1-year accuracy 3 / 12 met price target | 240%upside $100 | Buy Maintained | 1 Apr 2025 |
B of A Securities Jason Gerberry 35% 1-year accuracy 7 / 20 met price target | 366%upside $137 | Buy Maintained | 1 Apr 2025 |
Guggenheim Seamus Fernandez 32% 1-year accuracy 7 / 22 met price target | 444%upside $160 | Buy Reiterated | 12 Mar 2025 |
BTIG Thomas Shrader 11% 1-year accuracy 1 / 9 met price target | 444%upside $160 | Buy Reiterated | 24 Feb 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update
-- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 2 Dose-Finding Study of VAX-24 in Healthy Infants; Balance of Data Expected by End of 2025 -- -- Initiated Second and Final Stage of VAX-31 Infant Phase 2 Dose-Finding Study; Topline Safety, Tolerability and Immunogenicity Data from Primary Three-Dose Immunization Series Expected in Mid-2026, With Complete Booster Data Up to Nine Months Later --
Neutral
GlobeNewsWire
2 weeks ago
Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors
SAN CARLOS, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed Dr. Olivier Brandicourt, a veteran biopharmaceutical industry executive and the former Chief Executive Officer of Sanofi S.A., to its Board of Directors.
Negative
Zacks Investment Research
1 month ago
Vaxcyte Stock Plummets 56% in a Month: Here's the Reason
The downside comes after PCVX reports mixed results from a mid-stage study on its pneumococcal vaccine in infants.
Negative
Zacks Investment Research
1 month ago
Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr.
The decline in biotech stocks comes after FDA official Peter Marks' resignation, citing irreconcilable differences with the new HHS Secretary.
Negative
CNBC Television
1 month ago
Vaccine stocks fall following FDA resignation
Dr. Kavita Patel joins 'Fast Money' to talk the impact of FDA and HHS changes on vaccines, public health policy, and more.
Positive
Seeking Alpha
1 month ago
Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying Opportunity
Vaxcyte, Inc.'s positive results achieved from phase 2 dose-finding study using VAX-24 for the prevention of invasive pneumococcal disease in infants; Further post 4 dose data expected 2nd of 2025. It is expected that the 7 major pneumococcal disease markets are to reach a value of $11.6 billion by 2035. VAX-24 goes beyond that of Prevnar 20 in terms of targeting 4 more serotypes than it.
Negative
Investors Business Daily
1 month ago
Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns
Biotech stocks were hammered Monday after Peter Marks, a top FDA official, resigned amid a clash with Robert F. Kennedy Jr. The post Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns appeared first on Investor's Business Daily.
Neutral
Benzinga
1 month ago
Vaxcyte Plans To Drop Developing One Pneumococcal Conjugate Vaccine
Vaxcyte Inc. PCVX on Monday released topline results from its Phase 2 dose-finding study evaluating the safety, tolerability and immunogenicity of VAX-24, a 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), compared to Pfizer Inc's PFE Prevnar 20 (PCV20) in healthy infants.
Neutral
GlobeNewsWire
1 month ago
Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study
-- At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) -- -- At All Doses Evaluated, VAX-24 Elicited Substantial Immune Responses Following Primary Three-Dose Immunization Series; Topline Results Also Include Interim Booster Dose IgG Data Showing Robust Memory Responses Across All Doses -- -- Dose-Dependent Immune Responses Consistently Demonstrated and Little to No Evidence of Carrier Suppression Was Observed, Supporting Platform's Potential to Deliver Broadest-Spectrum Infant Pneumococcal Conjugate Vaccine (PCV) Candidates -- -- Company Selects VAX-24 Mid Dose (2.2mcg) as Basis for Optimized Dose Formulation for Advancement to Potential Infant Phase 3 Program, Pending Topline VAX-31 Infant Phase 2 Study Readout -- -- Company Announces VAX-XL, Third-Generation PCV Candidate Designed to Further Expand Spectrum of Coverage -- -- Company to Host Webcast/Conference Call Today at 8:00 a.m. ET / 5:00 a.m.
Neutral
GlobeNewsWire
1 month ago
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study
SAN CARLOS, Calif., March 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tomorrow, March 31, 2025, at 8:00 a.m. Eastern Time to present topline results from the VAX-24 infant Phase 2 study. This study is evaluating the safety, tolerability and immunogenicity of VAX-24, the Company's 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), compared to Prevnar 20® in healthy infants.
Charts implemented using Lightweight Charts™